Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 1;11(2):425.
doi: 10.3390/biomedicines11020425.

Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement

Mariola Świderek-Matysiak  1 , Magdalena Oset  1 , Małgorzata Domowicz  1 , Grażyna Galazka  1 , Magdalena Namiecińska  1 , Mariusz Stasiołek  1
Affiliations

Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement

Mariola Świderek-Matysiak et al. Biomedicines. .

Abstract

Background: Diagnosis of multiple sclerosis (MS) is established on criteria according to clinical and radiological manifestation. Cerebrospinal fluid (CSF) analysis is an important part of differential diagnosis of MS and other inflammatory processes in the central nervous system (CNS).

Methods: In total, 242 CSF samples were collected from patients undergoing differential MS diagnosis because of the presence of T2-hyperintensive lesions on brain MRI. The non-MS patients were subdivided into systemic inflammatory diseases with CNS involvement (SID) or cerebrovascular diseases (CVD) or other non-inflammatory diseases (NID). All samples were analyzed for the presence of oligoclonal bands and ELISA was performed for detection of: INF gamma, IL-6, neurofilaments light chain (NF-L), GFAP, CHI3L1, CXCL13, and osteopontin.

Results: The level of IL-6 (p = 0.024), osteopontin (p = 0.0002), and NF-L (p = 0.002) was significantly different among groups. IL-6 (p = 0.0350) and NF-L (p = 0.0015) level was significantly higher in SID compared to NID patients. A significantly higher level of osteopontin (p = 0.00026) and NF-L (p = 0.002) in MS compared to NID population was noted. ROC analysis found weak diagnostic power for osteopontin and NFL-L.

Conclusions: The classical and non-standard markers of inflammatory process and neurodegeneration do not allow for sufficient differentiation between MS and non-MS inflammatory CNS disorders. Weak diagnostic power observed for the osteopontin and NF-L needs to be further investigated.

Keywords: cerebrospinal fluid; differential diagnosis; interleukin 6; multiple sclerosis; neurofilaments light chain; oligoclonal bands; osteopontin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CSF concentration of IL6, OPN and NF-L. IL-6 (p = 0.035) and NF-L (p = 0.002) level was significantly higher in SID compared to NID patients. Significantly higher level of OPN (p = 0.000) and NF-L (p = 0.002) in MS compared to NID population was noted. * means significant differences p < 0.05; ** means significant differences p < 0.001.
Figure 2
Figure 2
ROC analysis found statistically significant AUC for OPN and NFL-L. AUC was 0.68 for both OPN and NF-L (CI 95% 0.6–0.7, p < 0.005 for both biomarkers).
See this image and copyright information in PMC

References

    1. Oh J., Vidal-Jordana A., Montalban X. Multiple sclerosis: Clinical aspects. Curr. Opin. Neurol. 2018;31:752–759. doi: 10.1097/WCO.0000000000000622. - DOI - PubMed
    1. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:62–173. doi: 10.1016/S1474-4422(17)30470-2. - DOI - PubMed
    1. Wattjes M.P., Ciccarelli O., Reich D.S., Banwell B., de Stefano N., Enzinger C., Fazekas F., Filippi M., Frederiksen J., Gasperini C., et al. Magnetic Resonance Imaging in Multiple Sclerosis Study Group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653–670. - PubMed
    1. Solomon A.J., Naismith R.T., Cross A.H. Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice. Neurology. 2019;92:26–33. doi: 10.1212/WNL.0000000000006583. - DOI - PMC - PubMed
    1. Solomon A.J., Bourdette D.N., Cross A.H., Applebee A., Skidd P.M., Howard D.B., Spain R.I., Cameron M.H., Kim E., Mass M.K., et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016;87:1393–1399. doi: 10.1212/WNL.0000000000003152. - DOI - PMC - PubMed